Literature DB >> 22535710

Increased systemic inflammatory interleukin-1ß and interleukin-6 during agitation as predictors of Alzheimer's disease.

T Honma1, K Hatta, Y Hitomi, Y Kambayashi, Y Hibino, T Konoshita, H Nakamura.   

Abstract

OBJECTS: Identification of biomarkers for Alzheimer's disease (AD) is important for its early diagnosis and prevention and a key in advancing our understanding of its pathophysiology. The aim of this study was to determine whether systemic inflammatory interleukin-1ß (IL-1ß) and interleukin-6 (IL-6) as well as hypertension (HT), diabetes mellitus (DM), and body mass index (BMI) are predictors of AD.
METHODS: We performed a 10-year follow-up study on 133 elderly who were institutionalized in a nursing home. The associations of IL-1ß and IL-6 at both rest and agitation, as well as HT, DM, and BMI at baseline, were analyzed with the incidences of vascular dementia (VD) and AD during a 10-year follow-up period.
RESULTS: The Kaplan-Meier method with log-rank test and Cox regression analyses for the total of 133 subjects showed significantly higher incidences of both VD and AD in subjects with DM or HT at baseline. Resting IL-1ß or IL-6 value, or agitation score, was not significantly associated with the subsequent development of VD or AD. The analyses of 40 subjects who had shown agitation at least once in the previous 3 months demonstrated that IL-1ß and IL-6 values at the agitation stage were significantly associated with AD, but not with VD.
CONCLUSION: Our results indicate that systemic inflammatory IL-1ß and IL-6 at the agitation stage are risk factors for the development of AD, but not VD. Inflammatory mechanisms for AD seem to be causal and specific to the development of AD.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22535710     DOI: 10.1002/gps.3816

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  9 in total

1.  Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease.

Authors:  John A McIntyre; Curtis J Ramsey; Bruce D Gitter; Andrew J Saykin; Dawn R Wagenknecht; Paul A Hyslop
Journal:  Autoimmunity       Date:  2015-02-12       Impact factor: 2.815

Review 2.  Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview.

Authors:  Frederic Brosseron; Marius Krauthausen; Markus Kummer; Michael T Heneka
Journal:  Mol Neurobiol       Date:  2014-02-25       Impact factor: 5.590

Review 3.  Neuroinflammation in Alzheimer's disease.

Authors:  Fengjin Zhang; Linlan Jiang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-01-30       Impact factor: 2.570

4.  Alterations in Alzheimer's Disease-Associated Gene Expression in Severe Obstructive Sleep Apnea Patients.

Authors:  Hsueh-Yu Li; Ming-Shao Tsai; Chung-Guei Huang; Robert Y L Wang; Li-Pang Chuang; Ning-Hung Chen; Chi-Hung Liu; Cheng-Ming Hsu; Wen-Nuan Cheng; Li-Ang Lee
Journal:  J Clin Med       Date:  2019-09-01       Impact factor: 4.241

Review 5.  Recent Trends in the Management of Alzheimer's Disease: Current Therapeutic Options and Drug Repurposing Approaches.

Authors:  Rakesh K Singh
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

Review 6.  Obstructive Sleep Apnea-hypopnea Syndrome as a Novel Potential Risk for Aging.

Authors:  Yayong Li; Yina Wang
Journal:  Aging Dis       Date:  2021-04-01       Impact factor: 6.745

7.  Associations of streptococci and fungi amounts in the oral cavity with nutritional and oral health status in institutionalized elders: a cross sectional study.

Authors:  Hanako Sato; Akira Yano; Yu Shimoyama; Toshiro Sato; Yukiko Sugiyama; Mitsuo Kishi
Journal:  BMC Oral Health       Date:  2021-11-19       Impact factor: 2.757

8.  Low-dose lipopolysaccharide (LPS) inhibits aggressive and augments depressive behaviours in a chronic mild stress model in mice.

Authors:  Yvonne Couch; Alexander Trofimov; Natalyia Markova; Vladimir Nikolenko; Harry W Steinbusch; Vladimir Chekhonin; Careen Schroeter; Klaus-Peter Lesch; Daniel C Anthony; Tatyana Strekalova
Journal:  J Neuroinflammation       Date:  2016-05-16       Impact factor: 8.322

Review 9.  Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer's disease in Japan.

Authors:  William Montgomery; Kaname Ueda; Margaret Jorgensen; Shari Stathis; Yuanyuan Cheng; Tomomi Nakamura
Journal:  Clinicoecon Outcomes Res       Date:  2017-12-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.